Showing 1 - 20 results of 74 for search 'Camillo Porta', query time: 0.04s Refine Results
  1. 1
    Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer

    Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  2. 2
    ASCO 2007: “Translating Research into Practice”. Report from the 34th Annual Meeting of the American Society of Clinical Oncology

    ASCO 2007: “Translating Research into Practice”. Report from the 34th Annual Meeting of the American Society of Clinical Oncology by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  3. 3
    Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses

    Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunothe... by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  4. 4
    Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system

    Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system by Camillo Porta

    Published 2020-05-01
    Get full text
    Article
  5. 5
    RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane

    RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane by Camillo Porta

    Published 2020-04-01
    Get full text
    Article
  6. 6
    Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses

    Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunothe... by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  7. 7
    Oncology Reviews: reasons for a new oncology journal

    Oncology Reviews: reasons for a new oncology journal by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  8. 8
    Oncology Reviews: reasons for a new oncology journal

    Oncology Reviews: reasons for a new oncology journal by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  9. 9
    ASCO 2007: “Translating Research into Practice”. Report from the 34th Annual Meeting of the American Society of Clinical Oncology

    ASCO 2007: “Translating Research into Practice”. Report from the 34th Annual Meeting of the American Society of Clinical Oncology by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  10. 10
    RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer

    RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer by Camillo Porta

    Published 2014-06-01
    Get full text
    Article
  11. 11
    To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value

    To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  12. 12
    To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value

    To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  13. 13
    Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

    Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time by Camillo Porta

    Published 2011-09-01
    Get full text
    Article
  14. 14
    Hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

    Hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma by Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  15. 15
    Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis

    Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis by Mimma Rizzo, Silvia Chiellino, Angela Gernone, Camillo Porta, Camillo Porta

    Published 2022-10-01
    Get full text
    Article
  16. 16
    The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia

    The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia by Camillo Porta, Federica Tagliani

    Published 2011-12-01
    Get full text
    Article
  17. 17
    Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

    Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? by Francesca Negri, Camillo Porta

    Published 2021-09-01
    Get full text
    Article
  18. 18
    Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

    Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence by Mimma Rizzo, Camillo Porta

    Published 2017-08-01
    Get full text
    Article
  19. 19
    Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma

    Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma by Chiara Paglino, Camillo Porta

    Published 2011-12-01
    Get full text
    Article
  20. 20
    Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient

    Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient by Camillo Porta, Camillo Porta, Alessandra Ferrari, Anna M. Czarnecka, Cezary A. Szczylik

    Published 2017-06-01
    Get full text
    Article

Search Tools: